Pharmaceutical Crystallization
Source abstract
Abstract
Crystallization is crucial in the pharmaceutical industry as a separation process for intermediates and as the final step in the manufacture of active pharmaceutical ingredients (APIs). In this perspective article to celebrate 10 years of Crystal Growth & Design, we focus on three areas related to crystallization in the pharmaceutical industry: (1) advances in our understanding of the fundamentals of nucleation, (2) production and scale-up of novel solid forms, and (3) continuous processing. While the areas discussed are not new, they are areas, in our opinion, of significant current interest to the community engaged in crystallization in the pharmaceutical industry.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Crystallization and Solubility Studies · Drug Solubulity and Delivery Systems · Analytical Chemistry and Chromatography
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Chemical Engineering, Massachusetts Institute of Technology, 77 Massachusetts Avenue 66-568, Cambridge, Massachusetts 02139, United States
Novartis-MIT Center for Continuous Manufacturing, 77 Massachusetts Avenue, Building 66, Cambridge, Massachusetts 02139, United States
References (64)
Show source-provided references
1. Sharaf M. A. · J. Chem. Phys. · 1982 · 77 · 151710.1063/1.443932 ↗
2. Galkin O. · P. Natl. Acad. Sci. U.S.A. · 2002 · 99 · 847910.1073/pnas.122055299 ↗
3. Georgalis Y. · Acta Crystallogr. D · 1997 · 53 · 69110.1107/S0907444997006847 ↗
4. Georgalis Y. · Acta Crystallogr. D · 1997 · 53 · 70310.1107/S0907444997006859 ↗
5. Igarashi K. · J. Cryst. Growth · 1999 · 204 · 19110.1016/S0022-0248(99)00181-5 ↗
6. Pontoni D. · Prog. Coll. Polym. Sci. · 2004 · 123 · 227
7. Chattopadhyay S. · Cryst. Growth Des. · 2005 · 5 · 52310.1021/cg0497344 ↗
8. Garetz B. A. · Phys. Rev. Lett. · 2002 · 8910.1103/PhysRevLett.89.175501 ↗
9. tenWolde P. R. · Science · 1997 · 277 · 197510.1126/science.277.5334.1975 ↗
10. Moroni D. · Phys. Rev. Lett. · 2005 · 9410.1103/PhysRevLett.94.235703 ↗
11. Santiso E. E. · J. Chem. Phys. · 2011 · 134 · 064109-(1−17)10.1063/1.3548889 ↗
12. Ostwald W. F. · Z. Phys. Chem. · 1897 · 22 · 28910.1515/zpch-1897-2233 ↗
13. Bernstein J. · 2002
14. Hilfiker R. · 200610.1002/3527607889 ↗
15. Burger A. · Mikrochim. Acta · 1979 · 25910.1007/BF01197379 ↗
16. Burger A. · Mikrochim. Acta · 1979 · 27310.1007/BF01197380 ↗
17. Woo X. Y. · Cryst. Growth Des. · 2009 · 9 · 15610.1021/cg800095z ↗
18. Lindenberg C. · Cryst. Growth Des. · 2009 · 9 · 112410.1021/cg800934h ↗
19. Alvarez A. J. · Cryst. Growth Des. · 2010 · 10 · 221910.1021/cg901496s ↗
20. European Medicines Agency, L., 18 June 2008, Doc. Ref. EMEA/265069 / 2008, Rev. 1.
21. Singhal D. · Adv. Drug Delivery Rev. · 2004 · 56 · 33510.1016/j.addr.2003.10.008 ↗
22. Chemburkar S. R. · Org. Process Res. Dev. · 2000 · 4 · 41310.1021/op000023y ↗
23. Laird T. · Org. Process Res. Dev. · 2004 · 8 · 30110.1021/op0499268 ↗
24. Mukuta T. · Cryst. Growth Des. · 2005 · 5 · 142910.1021/cg049646j ↗
25. Lu J. · Front. Chem. Eng. China · 2010 · 4 · 3710.1007/s11705-009-0294-2 ↗
26. Prashad M. · Org. Proc. Res. Dev. · 2010 · 14 · 87810.1021/op100115u ↗
27. Berkovitchyellin Z. · J. Am. Chem. Soc. · 1985 · 107 · 311110.1021/ja00297a017 ↗
28. Davey R. J. · J. Am. Chem. Soc. · 1997 · 119 · 176710.1021/ja9626345 ↗
29. He X. R. · J. Pharm. Sci. · 2001 · 90 · 37110.1002/1520-6017(200103)90:3<371::AID-JPS12>3.0.CO;2-N ↗
30. Deij M. A. · Cryst. Growth Des. · 2007 · 7 · 77810.1021/cg060885b ↗
31. Gavezzotti A. · CrystEngComm · 2002 · 34310.1039/B202063G ↗
32. Thayer A. M. · Chem. Eng. News · 2007 · 85 · 1710.1021/cen-v085n025.p017 ↗
33. McNamara D. P. · Pharm. Res. · 2006 · 23 · 188810.1007/s11095-006-9032-3 ↗
34. Stanton M. K. · Cryst. Growth Des. · 2009 · 9 · 134410.1021/cg8005019 ↗
35. Cheney M. L. · Cryst. Growth Des. · 2010 · 10 · 440110.1021/cg100514g ↗
36. Etter M. C. · Acc. Chem. Res. · 1990 · 23 · 12010.1021/ar00172a005 ↗
37. Etter M. C. · J. Phys. Chem. · 1991 · 95 · 460110.1021/j100165a007 ↗
38. Sarma B. · Cryst. Growth Des. · 2009 · 9 · 154610.1021/cg801145c ↗
39. Chiarella R. A. · Cryst. Growth Des. · 2007 · 7 · 122310.1021/cg070218y ↗
40. Rodriguez-Hornedo N. · Mol. Pharmaceutics · 2006 · 3 · 36210.1021/mp050099m ↗
41. Childs S. L. · CrystEngComm · 2008 · 10 · 85610.1039/b715396a ↗
42. Zhang G. G. Z. · J. Pharm. Sci. · 2007 · 96 · 99010.1002/jps.20949 ↗
43. Gagniere E. · Cryst. Growth Des. · 2009 · 9 · 337610.1021/cg801019d ↗
44. Yu Z. Q. · Cryst. Growth Des. · 2010 · 10 · 238210.1021/cg100198u ↗
45. Gagniere E. · J. Cryst. Growth · 2009 · 311 · 268910.1016/j.jcrysgro.2009.02.040 ↗
46. Padrela L. · Eur. J. Pharm. Sci. · 2009 · 38 · 910.1016/j.ejps.2009.05.010 ↗
47. Medina C. · J. Pharm. Sci. · 2010 · 99 · 169310.1002/jps.21942 ↗
48. Good D. J. · Cryst. Growth Des. · 2009 · 9 · 225210.1021/cg801039j ↗
49. Sheikh A. Y. · CrystEngComm · 2009 · 11 · 50110.1039/B813058B ↗
50. Almarsson O. · Chem. Commun. · 2004 · 17 · 188910.1039/b402150a ↗
51. Childs S. L. · J. Am. Chem. Soc. · 2004 · 126 · 1333510.1021/ja048114o ↗
52. Banerjee R. · Cryst. Growth Des. · 2005 · 5 · 229910.1021/cg050125l ↗
53. Remenar J. F. · J. Am. Chem. Soc. · 2003 · 125 · 845610.1021/ja035776p ↗
54. Hickey M. B. · Eur. J. Pharm. Biopharm. · 2007 · 67 · 11210.1016/j.ejpb.2006.12.016 ↗
55. Morissette S. L. · Adv. Drug Delivery Rev. · 2004 · 56 · 27510.1016/j.addr.2003.10.020 ↗
56. Bettinetti G. · J. Pharm. Sci. · 2000 · 89 · 47810.1002/(SICI)1520-6017(200004)89:4<478::AID-JPS5>3.0.CO;2-5 ↗
57. Vishweshwar P. · Chem. Commun. · 2005 · 36 · 460110.1039/b501304f ↗
58. Trask A. V. · Cryst. Growth Des. · 2005 · 5 · 101310.1021/cg0496540 ↗
59. Nangia A. · Cryst. Growth Des. · 2009 · 9 · 333910.1021/cg900554h ↗
60. Lawton S. · Org. Process Res. Dev. · 2009 · 13 · 135710.1021/op900237x ↗
61. Myerson A. S. · 2002
62. Randolph A. D. · 1988
63. Su Y. F. · J. Solid State Chem. · 2007 · 180 · 262510.1016/j.jssc.2007.06.033 ↗
64. Sultana M. · 2010